World models are the hottest race in AI right now. Every frontier lab is building one - but they're all aimed at robotics, generalist agents, autonomous vehicles. None at oncology. We're the first.
We're building a world model for oncology. AI that can predict and simulate disease progression based on a patient's full history across imaging, treatment, and clinical data.
That's our vision. Today, we're shipping clinical AI tools for medical imaging that serve as the building blocks (for example, automated body-composition analysis, tumor detection and tumor characterization) toward that vision. These are already powering studies in leading US hospitals, and they're how we're generating revenue while we build toward something bigger.
Medical imaging AI today looks at a single scan in isolation. It doesn't account for prior scans, treatment history, or how the disease has evolved. Radiologists carry that longitudinal understanding in their heads, but their software doesn't. We think that's one of the fundamental limitations holding back AI in cancer care.
I'm Luca and my co-founder is Angelica. We started working together in 2023 at Stanford's Department of Medicine. Between that and my time on Apple's Health AI team, we kept seeing world-class research that never reached the tools clinicians actually use. Nucleo exists to close that gap!
No comment highlights available yet. Please check back later!
About Nucleo on Product Hunt
“Automated cancer diagnostics”
Nucleo launched on Product Hunt on May 5th, 2026 and earned 86 upvotes and 1 comments, placing #15 on the daily leaderboard. World models are the hottest race in AI right now. Every frontier lab is building one - but they're all aimed at robotics, generalist agents, autonomous vehicles. None at oncology. We're the first.
Nucleo was featured in Pitch NYC (2 followers) on Product Hunt. Together, these topics include over 85 products, making this a competitive space to launch in.
Who hunted Nucleo?
Nucleo was hunted by Rajiv Ayyangar. A “hunter” on Product Hunt is the community member who submits a product to the platform — uploading the images, the link, and tagging the makers behind it. Hunters typically write the first comment explaining why a product is worth attention, and their followers are notified the moment they post. Around 79% of featured launches on Product Hunt are self-hunted by their makers, but a well-known hunter still acts as a signal of quality to the rest of the community. See the full all-time top hunters leaderboard to discover who is shaping the Product Hunt ecosystem.
Want to see how Nucleo stacked up against nearby launches in real time? Check out the live launch dashboard for upvote speed charts, proximity comparisons, and more analytics.
Rajiv Ayyangar
Hey PH!
We're building a world model for oncology. AI that can predict and simulate disease progression based on a patient's full history across imaging, treatment, and clinical data.
That's our vision. Today, we're shipping clinical AI tools for medical imaging that serve as the building blocks (for example, automated body-composition analysis, tumor detection and tumor characterization) toward that vision. These are already powering studies in leading US hospitals, and they're how we're generating revenue while we build toward something bigger.
Medical imaging AI today looks at a single scan in isolation. It doesn't account for prior scans, treatment history, or how the disease has evolved. Radiologists carry that longitudinal understanding in their heads, but their software doesn't. We think that's one of the fundamental limitations holding back AI in cancer care.
I'm Luca and my co-founder is Angelica. We started working together in 2023 at Stanford's Department of Medicine. Between that and my time on Apple's Health AI team, we kept seeing world-class research that never reached the tools clinicians actually use. Nucleo exists to close that gap!